VANCOUVER, BC / ACCESS Newswire / March 26, 2026 / Aton Resources Inc. (TSX-V:AAN) ("Aton" or the "Company") updates investors on the first results from its reverse circulation percussion ("RC") drilling programme at the Abu Marawat deposit ("Abu Marawat"), located within the retained exploration areas of the Company's Abu Marawat Concession (the "Concession") in the Eastern Desert of Egypt. Highlights: The results from the first 14 holes of the 2025 RC infill drilling programme at Abu Marawat, AMP-214 to A ...

Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2][36] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][6] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [5][6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][38] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][38] - Empasiprubart is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and delayed graft function following kidney transplant [28][36] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][38] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to enhance patient outcomes [3][38]

Core Viewpoint - Katapult Holdings, Inc. (KPLT) is experiencing a significant stock price increase of 23.20 percent to $7.65 following the announcement of a definitive all-stock merger agreement with The Aaron's Company, Inc. and CCF Holdings LLC, aimed at creating an expanded omni-channel platform for non-prime consumers [1] Group 1 - The stock opened at $9.19 and has fluctuated between $7.01 and $9.23 on the Nasdaq [2] - The current bid is at $7.61 and the ask at $8.63, indicating active trading [2] - Trading volume has surged to 18,486,638, significantly higher than the average of 102,893 [2] Group 2 - Katapult's 52-week stock range is $5.08 to $24.34, with shares currently well above recent lows following the merger announcement [2]

Core Insights - Aton Resources Inc. has provided an update on the final results from its diamond drilling program at the Abu Marawat deposit in Egypt [1] Summary by Sections - The final results include data from the last 19 holes of the 2024-25 diamond drilling program, specifically holes AMD-196 to AMD-213, along with a re-entry of hole AMD-102 [1]

Core Insights - Axsome Therapeutics is presenting results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 for Alzheimer's disease agitation at the 2025 AAN Annual Meeting [1][2] - The company is also showcasing data from the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy and a network meta-analysis comparing SYMBRAVO® to oral CGRPs for migraine treatment [2] Alzheimer's Disease Agitation - Title of the presentation: "Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study" [3] - Oral presentation scheduled for April 7, 2025, from 11:27 to 11:33 a.m. PT [3] - Poster presentation on the same day from 12:09 to 12:45 p.m. PT [3] Narcolepsy - Title of the presentation: "AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY Trial" [3] - Oral presentation scheduled for April 8, 2025, from 10:45 to 11 a.m. PT [3] - Additional poster presentation titled "CRESCENDO: Results from a Survey of Symptom Burden and Quality of Life in Patients with Narcolepsy Type 1" on April 8, 2025, from 8 to 9 a.m. PT [3] Migraine - Title of the presentation: "Comparative Efficacy of AXS-07 vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis" [4] - Poster presentation scheduled for April 8, 2025, from 5 to 6 p.m. PT [4] - SYMBRAVO is a novel oral medication approved for acute migraine treatment, combining MoSEIC™ meloxicam and rizatriptan [5][6] Company Overview - Axsome Therapeutics focuses on developing innovative treatments for central nervous system disorders, with a portfolio that includes FDA-approved therapies for major depressive disorder, narcolepsy, and migraine [34][35] - AXS-05 is an investigational drug for Alzheimer's disease agitation and smoking cessation, utilizing a proprietary formulation of dextromethorphan and bupropion [32] - AXS-12 is under development for narcolepsy and has received FDA Orphan Drug Designation [33]

Core Insights - Johnson & Johnson presented new data from the 24-week pivotal Vivacity-MG3 study, demonstrating sustained disease control through treatment with nipocalimab in antibody-positive adult patients with generalized myasthenia gravis (gMG) [1][2] - The company filed a Biologics License Application (BLA) for nipocalimab in August 2024, which has been granted U.S. FDA Priority Review for the treatment of gMG [1][2] - Real-world studies indicate a significant unmet need for effective treatments for patients living with gMG, particularly among pregnant women and those receiving steroids [1][3] Company Developments - Johnson & Johnson announced that 12 abstracts, including two oral presentations, will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting, highlighting the potential of nipocalimab in treating gMG [1][4] - The ongoing open-label extension (OLE) study of nipocalimab shows long-term efficacy and safety, indicating sustained disease control in a broad population of antibody-positive gMG adult patients [6][11] - The company emphasizes its commitment to addressing critical unmet needs in the autoantibody disease space through innovative research and development [4][14] Industry Context - Myasthenia gravis (MG) is an autoantibody disease affecting approximately 700,000 people worldwide, with a significant portion being women of child-bearing potential [10][11] - The Phase 3 Vivacity-MG3 study was designed to measure sustained efficacy and safety in gMG patients with insufficient response to standard of care (SOC) therapy [11][12] - There is a growing recognition of the need for additional approved immunoselective therapies that are effective and have demonstrated safety profiles for individuals living with gMG [3][6]

Core Viewpoint - A class action lawsuit has been filed against The Aaron's Company Inc. in connection with its merger with IQVentures Holdings, LLC, alleging violations of the Securities Exchange Act of 1934 [1] Group 1: Lawsuit Details - The lawsuit was filed on February 13, 2024, in the United States District Court for the Northern District of Georgia [1] - The case is titled Koksal v. The Aaron's Company Inc., et al., Case No. 1:25-cv-00754-LMM [1] - The claims are made on behalf of individuals and entities that held securities of The Aaron's Company Inc. [1] Group 2: Merger Information - The proposed merger between Aaron's and IQVentures Holdings, LLC was announced on June 17, 2024 [1] - The merger was completed in October 2024 [1]

Group 1 - The Aaron's Company has completed its acquisition by IQVentures Holdings for $10.10 per share, resulting in an enterprise value of approximately $504 million [1] - The acquisition was initially announced on June 17, 2024, and received shareholder approval on September 25, 2024 [1] - Following the completion of the transaction, The Aaron's Company's common stock will cease trading and will no longer be listed on the NYSE [1] Group 2 - The CEO of The Aaron's Company stated that the acquisition marks the beginning of a new chapter aimed at enhancing customer lives through affordable lease and retail purchase options [2] - The combination of expertise and resources with IQVentures is expected to accelerate the omni-channel strategy and improve operational efficiency [2] Group 3 - J.P. Morgan Securities LLC served as the exclusive financial advisor to The Aaron's Company, while Stephens Inc. acted as the exclusive financial advisor to IQVentures [3] Group 4 - The Aaron's Company is a technology-enabled, omnichannel provider of lease-to-own and retail purchase solutions for appliances, electronics, furniture, and other home goods [4] - The company operates approximately 1,210 stores across 47 states and Canada, along with an e-commerce platform [4] - BrandsMart U.S.A. is a leading appliance retailer with 12 retail stores in Florida and Georgia [4] Group 5 - IQVentures is focused on investing in and building technology companies that shape the future, leveraging proprietary technology and shared services [5]

Acquisition Announcement - The Aaron's Company is set to complete its acquisition by IQVentures Holdings, LLC, with the transaction expected to finalize later today [1] - The acquisition was initially announced on June 17, 2024, and received shareholder approval on September 25, 2024 [1] Company Overview - The Aaron's Company is a technology-enabled, omnichannel provider of lease-to-own and retail purchase solutions for appliances, electronics, furniture, and other home goods [3] - The company operates approximately 1,210 stores across 47 states and Canada, alongside its e-commerce platform [3] - BrandsMart U.S.A., a subsidiary, is a leading appliance retailer with 12 stores in Florida and Georgia [3] IQVentures Overview - IQVentures is based in the Columbus, Ohio metropolitan area and focuses on investing in technology and companies that shape the future [4] - The firm has expertise in consumer and business financing, utilizing proprietary technology to enhance value for acquired companies [4] Advisory Roles - J.P. Morgan Securities LLC is the exclusive financial advisor for The Aaron's Company, while Stephens Inc. serves in the same capacity for IQVentures [2]

Core Viewpoint - Aaron's Company, Inc. reported a loss in Q2 2024, with revenues declining in both segments, missing consensus estimates and showing year-over-year declines [2][4]. Financial Performance - The adjusted loss per share was 7 cents, missing the Zacks Consensus Estimate of earnings of 3 cents, compared to adjusted earnings of 39 cents per share in the same quarter last year [2]. - Consolidated revenues decreased by 5.1% to $503.1 million, falling short of the Zacks Consensus Estimate of $510 million [2]. - Lease revenues and fees dropped 5.1% year over year to $335.7 million, while retail sales fell 5.7% to $139.5 million [3]. - Non-retail sales decreased by 3.1% to $22.1 million, but franchise royalties and other revenues increased by 1.7% to $5.9 million [3]. - E-commerce recurring revenues grew significantly by 79.4% due to new omnichannel lease decisions and customer acquisition programs [3]. Segment Analysis - In the Aaron's business segment, revenues declined by 5% year over year to $369.4 million, attributed to a 2% decrease in lease portfolio size and a 140 basis points drop in lease renewal rate to 86.8% [4]. - The BrandsMart segment saw revenues decrease by 5.8% to $135.4 million, primarily due to a 7.3% decline in comparable sales linked to reduced customer traffic [4]. Margins and EBITDA - Gross profit fell by 3.6% year over year to $272 million, while gross margin expanded by 90 basis points to 54.1% [5]. - The company reported an operating loss of $12.3 million compared to an operating profit of $11.3 million in the previous year [5]. - Adjusted EBITDA declined by 42.2% year over year to $24.5 million, with the adjusted EBITDA margin decreasing by 310 basis points to 4.9% [5]. Financial Position - Aaron's has agreed to be acquired by IQVentures for $10.10 per share, with an enterprise value of approximately $504 million [6]. - The company ended the quarter with cash and cash equivalents of $34.2 million, net debt of $181.6 million, and shareholders' equity of $657.7 million [6]. - In the first half of 2024, it utilized $6.9 million of cash from operating activities and reported a negative adjusted free cash flow of $39.2 million [6]. Dividend and Future Outlook - The company paid out dividends of $3.8 million in Q2 and declared a regular quarterly cash dividend of 12.5 cents per share, payable on October 3, 2024 [7]. - Due to the pending acquisition by IQVentures, Aaron's has withdrawn its 2024 guidance [7]. - Estimates for the company have trended downward, with a consensus estimate shift of -16.13% [8][10]. Industry Comparison - Aaron's is part of the Zacks Consumer Services - Miscellaneous industry, where Cimpress (CMPR) reported a revenue increase of 5.6% year over year [11]. - Cimpress is expected to post earnings of $0.30 per share for the current quarter, reflecting a year-over-year change of +76.5% [11].